Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors

Business Wire December 13, 2021

Revance Therapeutics Investor Alert

Newsfile December 12, 2021

REVANCE THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC

PR Newswire December 11, 2021

Revance Therapeutics Update

Newsfile December 11, 2021

Revance Therapeutics Shareholder Notice

Newsfile December 9, 2021

Revance Therapeutics Shareholder Alert

Newsfile December 8, 2021

Lost Money in Revance Therapeutics, Inc.?

Business Wire December 7, 2021

Revance Therapeutics Investor Alert

Newsfile December 7, 2021

Revance Therapeutics Investor Alert

Newsfile December 5, 2021

Revance Therapeutics Update

Newsfile December 4, 2021

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile December 3, 2021

Revance Therapeutics Shareholder Notice

Newsfile December 2, 2021

Revance Therapeutics Shareholder Alert

Newsfile December 1, 2021

Revance Therapeutics Investor Alert

Newsfile November 30, 2021

Revance Therapeutics Investor Alert

Newsfile November 28, 2021

Revance Therapeutics Update

Newsfile November 27, 2021

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

PR Newswire November 26, 2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations

Newsfile November 26, 2021

Revance Therapeutics Shareholder Notice

Newsfile November 25, 2021

Revance Therapeutics Shareholder Alert

Newsfile November 24, 2021